Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 158

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Randomized Phase II Study of Bortezomib Alone and Bortezomib in Combination With Docetaxel in Previously Treated Advanced Non–Small-Cell Lung Cancer

Fanucchi, Michael P., Fossella, Frank V., Belt, Robert, Natale, Ronald, Fidias, Panos, Carbone, David P., Govindan, Ramaswamy, Raez, Luis E., Robert, Francisco, Ribeiro, Maria, Akerley, Wallace, Kelly, Karen, Limentani, Steven A., Crawford, Jeffrey, Reimers, Hans-Joachim, Axelrod, Rita, Kashala, Oscar, Sheng, Shihong, Schiller, Joan H.·2006·Journal of Clinical Oncology

Abstract

Purpose: To evaluate the efficacy and toxicity of bortezomib ± docetaxel as second-line therapy in patients with relapsed or refractory advanced non–small-cell lung cancer (NSCLC). Patients and Methods: Patients were randomly assigned to bortezomib 1.5 mg/m 2(arm A) or bortezomib 1.3 mg/m 2 plus docetaxel 75 mg/m 2(arm B). A treatment cycle of 21 days comprised four bortezomib doses on days 1, 4, 8, and 11, plus, in arm B, docetaxel on day 1. Patients could receive unlimited cycles. The primary end point was response rate. Results: A total of 155 patients were treated, 75 in arm A and 80 in arm B. Baseline characteristics were comparable. Investigator-assessed response rates were 8% in arm A and 9% in arm B. Disease control rates were 29% in arm A and 54% in arm B. Median time to progression was 1.5 months in arm A and 4.0 months in arm B. One-year survival was 39% and 33%, and median survival was 7.4 and 7.8 months in arms A and B, respectively. Adverse effect profiles were as expected in both arms, with no significant additivity. The most common grade ≥ 3 adverse events were neutropenia, fatigue, and dyspnea (4% and 53%, 19% and 26%, and 17% and 14% of patients in arms A and B, respectively). Conclusion: Bortezomib has modest single-agent activity in patients with relapsed or refractory advanced NSCLC using this schedule, with minor enhancement in combination with docetaxel. Additional investigation of bortezomib in NSCLC is warranted in combination with other drugs known to be active, or using different schedules.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2006.06.1853

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 158

Metadata

Authors
Fanucchi, M. P., Fossella, F. V., Belt, R., Natale, R., Fidias, P., Carbone, D. P., Govindan, R., Raez, L. E., Robert, F., Ribeiro, M., Akerley, W., Kelly, K., Limentani, S. A., Crawford, J., Reimers, H.-J., Axelrod, R., Kashala, O., Sheng, S., & Schiller, J. H.
Venue
Journal of Clinical Oncology
Published
2006-11-01
Volume
24
Issue
31
Pages
5025-5033
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2136951601
Cited by
158
References
1
FWCI
16.10
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Randomized Phase II Study of Bortezomib Alone and Bortezomib in Combination With Docetaxel in Previously Treated Advanced Non–Small-Cell Lung Cancer. https://app.cochat.ai/papers/10.1200/jco.2006.06.1853
The paper
Fanucchi, M. P., Fossella, F. V., Belt, R., Natale, R., Fidias, P., Carbone, D. P., Govindan, R., Raez, L. E., Robert, F., Ribeiro, M., Akerley, W., Kelly, K., Limentani, S. A., Crawford, J., Reimers, H.-J., Axelrod, R., Kashala, O., Sheng, S., & Schiller, J. H. (2006). Randomized Phase II Study of Bortezomib Alone and Bortezomib in Combination With Docetaxel in Previously Treated Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2006.06.1853

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.